Nektar Therapeutics says it has $952.9 million in cash and investments as of September 30, 2026.

Nov 13, 2026, 6:09 AM ETResultsRead the original at SEC EDGAR

Good for NKTR

Nektar's prior quarterly update reported a loss, but the company says its cash can last past its first Phase 3 trial results in summer 2028. That supports its ability to reach those results, though the timeline is a forecast.

NKTR · Nektar Therapeutics

AI read · Good for NKTR

The AI's read

That gives Nektar a stated cash runway through its first major trial results, which could let it reach them without raising funds first. Its prior quarterly update reported a loss, so spending remains a concern. Nektar also warns that its cash estimate could prove wrong.

Get alerts for NKTR

Follow Nektar Therapeutics (NKTR) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for NKTR

Free on the App Store and Google Play, or on the web.